



ESMO VIRTUAL PRECEPTORSHIP

21-22 JUNE 2021

Co-Chairs

Nicola Fazio, Italy Angela Lamarca, United Kingdom





ESMO VIRTUAL PRECEPTORSHIP PROGRAMME

GASTROENTEROPANCREATIC AND LUNG NEUROENDOCRINE NEOPLASMS

Multidisciplinary management, standards of care and future perspectives

21-22 June 2021

CO-CHAIRS: Nicola Fazio, Italy SPEAKERS: Teresa Alonso Gordoa, Spain

Angela Lamarca, United Kingdom

Eric Baudin, France Emilio Bertani, Italy Jérôme Cros, France

Rocio Garcia-Carbonero, Spain Guillaume Nicolas, Switzerland

Anja Rinke, Germany Francesca Spada, Italy Juan Valle, United Kingdom

LEARNING OBJECTIVES

- Familiarise with the epidemiology, classification and prognostication of Gastroenteropancreatic (GEP) and Lung Neuroendocrine Neoplasms (NEN) patients
- Introduce principles of diagnostic and therapeutic strategy and the role of a multidisciplinary team
- Integrate different therapies in patients with advanced disease
- Update of new developments, clinical trials and unmet needs

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For the future details please refer to esmo.org

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office Education Department Via Ginevra 4 6900 Lugano Switzerland

Email: courses@esmo.org

www.esmo.org



Monday, 21 June 2021

| 16:00-16:05 5' | Welcome and introduction | Nicola Fazio, IT Angela Lamarca, UK |
|--------------------|--|--|
| 16:05-16:55 50' | SESSION 1 Current State of the Art on GEP NENs - Part 1 | Chairs/Moderators: Nicola Fazio, IT Angela Lamarca, UK |
| 10' | Pathologist (terminology and classifications of GEP NENs) | Jérôme Cros, FR |
| 10' | Locally advanced GEP-NET management (including G3) | Emilio Bertani, IT |
| 15' | Somatostatin analogues in GEP NETs | Teresa Alonso Gordoa, ES |
| 15' | Q&A | Faculty |

16:55-17:10 Break

| 17:10-18:10 60' | SESSION 2 Current State of the Art on GEP NENs - Part 2 | Chairs/Moderators: Angela Lamarca, UK Nicola Fazio, IT |
|--------------------|---|--|
| 15' | Eligibility criteria for Peptide Receptor Radionuclide Therapy (PRRT) and indications in GEP NET patients | Guillaume Nicolas, CH |
| 15' | Molecular targeted agents in GEP NET patients | Rocio Garcia-Carbonero, ES |
| 15' | Chemotherapy in GEP NENs | Juan Valle, UK |
| 15' | Q&A | Faculty |

| 18:10-19:15 65' | Case presentations | Chairs/Moderators: Nicola Fazio, IT Angela Lamarca, UK |
|--------------------|---|--|
| 60' | Participants clinical case discussion (4x15') | Faculty |
| 5' | Closing of Day 1 | Nicola Fazio, IT |

Tuesday, 22 June 2021

| 16:00-17:00 60' | SESSION 4 Current State of the Art on Lung NETs | Chairs/Moderators: Angela Lamarca, UK Nicola Fazio, IT |
|--------------------|--|--|
| 15' | Pathologist (terminology and classifications of Lung NENs) | Jérôme Cros, FR |
| 15' | SSA in Lung NETs | Francesca Spada, IT |
| 15' | Systemic therapy in Lung NETs | Eric Baudin, FR |
| 15' | Q&A | Faculty |

| 17:00-17:30 30' | SESSION 5 Case presentations | Chairs/Moderators: Nicola Fazio, IT Angela Lamarca, UK |
|---------------------|---|--|
| 30' | Participants clinical case discussion (2x15') | Faculty |
| 17:30-17:45 | Break | |
| 17:45-19:25 100' | SESSION 6 What do I need to know about | Chairs/Moderators: Nicola Fazio, IT Angela Lamarca, UK |
| 10' | Carcinoid syndrome: symptoms and management | Anja Rinke, DE |
| 10' | Carcinoid Heart Disease: screening and management | Francesca Spada, IT |
| 20' | Wait and see: is it really an option? | Angela Lamarca, UK |
| 10' | NET G3: why does morphology matter? | Teresa Alonso Gordoa, ES |
| 15' | Q&A | Faculty |
| 30' | Participants clinical case discussion (2x15') | Faculty |
| 5' | Closing of Day 2 | Nicola Fazio, IT |